Other tumor-targeting strategies, such as antibody-drug conjugates (ADCs), consist of large proteins complexed with chemotherapy (molecular weight 100,000) that require binding to a unique target on the cell surface, followed by endocytosis to deliver the protein complex through the cell membrane. The process generally requires the use ultra-potent payload toxins due to the complexity of the absorption process. In contrast, HDCs are small molecule drug conjugates (molecular weight
Antibody-Drug Conjugates (ADCs), offer a solution to these limitations by delivering potent anti-cancer payloads more directly to tumors.
HDCs offer many of the advantages of antibody-driven targeted delivery with potentially broader applicability. Because of its unique properties, Hsp90 (heat shock protein 90) may represent one of the most compelling targets for delivering drug payloads to tumors.